Trilostane in advanced breast cancer

Bibliography

• BEATSON GT: On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet (1896) ii:104-107.
   Google Scholar
• JENSEN EV, JACOBSEN HI: Basic guides to the mechanism of estrogen action. Recent Progress in Hormone Research (1962) 18:387-414.
   Google Scholar
• COLE MP, JONES AC, TODD IDH: A new anti-oestrogenic agent in late breast cancer: an early clinical appraisal of ICI146474. Br. J. Cancer (1971) 25:270-275.
   PubMed Web of Science ®Google Scholar
• BUZDAR AU, JONES SE, VOGEL CL: A Phase III trial comparing anastrozole (1 and 10 milligrams) a potent and selective aromatase inhibitor, with megestrol acetate in post menopausal women with advanced breast carcinoma. Arimidex study Group. Cancer (1997) 79:730-739
   PubMed Web of Science ®Google Scholar
• HOWELL A, DOWNEY S, ANDERSON E: New endocrine therapies for breast cancer. Eur. J. Cancer (1996) 32A:576-588.
   PubMed Web of Science ®Google Scholar
• JORDAN VC: Tamoxifen: a personal retrospective. The Lancet Oncol. (2000) 1:43-49.
   PubMedGoogle Scholar
• NORMANNO N, DIMAIO M, DE MAIO E et al.: Mechanism of endocrine resistance and novel therapeutic strategies in breast cancer. Endocrine Related Cancer (2005) 12:721-747.
   PubMed Web of Science ®Google Scholar
• NEVEN P, VERGOTE I: Tamoxifen screening and new oestrogen receptor modulators. Baillieres Best Pract. Res. Clin. Obstet. Gynaecol. (2001) 15:365-380.
   Web of Science ®Google Scholar
• O’REGAN RM, JORDAN VC: Tamoxifen to raloxifene and beyond. Semin. Oncol. (2001) 28:260-273.
   PubMedGoogle Scholar
• ROBERTSON JFR: Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treat. Rev. (2004) 30:695-706.
   PubMedGoogle Scholar
• HARPER-WYNNE C, DOWSETT M: Recent advances in the clinical application of aromatase inhibitors. J. Steroid Biochem. Mol. Biol. (2001) 76:179-186.
   PubMedGoogle Scholar
• DODWELL D, WARDLEY A, JOHNSTON S: Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. Breast J. (2006) Epub ahead of print.
   Google Scholar
• POTTS GO, CREANGE JE, HARDING HR, SCHANE HP: Trilostane, an orally active inhibitor of steroid biosynthesis. Steroids (1978) 32:257-267.
   PubMed Web of Science ®Google Scholar
• BEARDWELL CG, HINDLEY AC, WILKINSON PM, ST JOHN J, BU’LOCK D: Hormonal changes in postmenopausal women with breast cancer treated with trilostane and dexamethasone. Clin. Endocrinol. (1985) 23:413-421.
   PubMedGoogle Scholar
• RABE T, KIESEL L, KELLERMAN J, WEIDENHAMMER K, RUNNEBAUM B, POTTS GO: Inhibition of human placental progesterone synthesis and aromatase activity by synthetic steroidogenic inhibitors in vitro. Fertil. Steril. (1983) 39:829-835.
   PubMedGoogle Scholar
• TONETTI DA, JORDAN VC: The oestrogen receptor: a logical target for the prevention of breast cancer with antioestrogens. J. Mammary Gland Biol. Neoplasia (1999) 4:401-413
   PubMedGoogle Scholar
• WITTLIFF JL: Steroid-hormone receptors in breast cancer. Cancer (1984) 53:630-643.
   PubMed Web of Science ®Google Scholar
• KUIPER GG, ENMARK E, PELTO-HUIKKO M, NILSSON M, GUSTAFSSON JA: Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA (1996) 93:5925-5930.
   PubMed Web of Science ®Google Scholar
• GUSTAFSSON JA: Estrogen receptor beta – a new dimension in estrogen mechanism of action. J. Endocrinol. (1999) 163:379-383.
   PubMed Web of Science ®Google Scholar
• PUDDEFOOT JR, BARKER S, GLOVER HR, MALOUITRE SD, VINSON GP: Non-competitive steroid inhibition of oestrogen receptor functions. Int. J. Cancer. (2002) 101:17-22.
   PubMedGoogle Scholar
• BARKER S: Antioestrogens in the treatment of breast cancer: current status and future directions. Curr. Opin. Investigational Drugs (2003) 4:652-657
   PubMedGoogle Scholar
• BARKER S, MALOUITRE SD, GLOVER HR, PUDDEFOOT JR, VINSON GP: Comparison of effects of 4-hydroxy tamoxifen and trilostane on oestrogen-regulated gene expression in MCF-7 cells: up-regulation of oestrogen receptor beta. J. Steroid Biochem. Molecular Biol. (2006) In press.
   Google Scholar
• BARKER S, GLOVER HR, MALOUITRE SDM, PUDDEFOOT JR, VINSON GP: Trilostane blocks actions of oestrogens through two pathways. Eur. J. Cancer (2003) 1(Suppl.):20.
   Google Scholar
• HALL JM, MCDONNELL DP: The estrogen receptor beta-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology (1999) 140:5566-5578.
   PubMed Web of Science ®Google Scholar
• BARDIN A, BOULLE N, LAZENNEC G, VIGNON F, PUJOL P: Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer (2004) 11:537-551.
   PubMed Web of Science ®Google Scholar
• ESSLIMANI-SAHLA M, SIMONY-LAFONTAINE J, KRAMAR A et al.: Estrogen receptor beta (ER β) level but not its ER β Cx variant helps to predict tamoxifen resistance in breast cancer. Clin. Cancer Res. (2004) 10:5769-5776.
   PubMedGoogle Scholar
• ROBINSON DT, EARNSHAW RJ, MITCHELL R, POWLES P, ANDREWS RS, ROBERTSON WR: The bioavailability and metabolism of trilostane in normal subjects, a comparitive study using high pressure liquid chromatographic and quantitative cytochemical assays. J. Steroid Biochem. (1984) 21:601-605.
   PubMedGoogle Scholar
• MCGEE JP, SHAW PN: The pharmacokinetics of trilostane and ketotrilostane in an interconverting system in the rat. Pharm. Res. (1992) 9:464-468.
   PubMedGoogle Scholar
• POWLES P, ROBINSON DT, ANDREWS RS: Determination of trilostane and ketotrilostane in human plasma by high performance liquid chromatography. J. Chromatography (1984) 311:434-442.
   PubMedGoogle Scholar
• BROWN RR, STROSHANE RM, BENZIGER DP: High performance liquid chromatographic assay for trilostane and its major metabolite, 17-ketotrilostane, in human plasma. J. Chromatography (1985) 339:440-444.
   PubMedGoogle Scholar
• MURRAY R, PITT P: Effectiveness of adrenal blockade with trilostane after prior tamoxifen therapy in women with advanced breast cancer. J. Steroid Biochem. (1987) 28:1025-1030.
   Google Scholar
• T’HOOFT-ANDRY M, FOCAN C, CLARYSSE A, MICHEL J, HEUSON JC, PARIDAENS R: Trilostane plus hydrocortisone in postmenopausal women with advanced breast cancer. A Phase II study of the Belgian Society of Medical Oncology. International Symposium on Hormonal Manipulation Of Cancer; Peptides, Growth Factors And New (Anti) Steroidal Agents. Rotterdam, Holland (1986) Abstr. 114.
   Google Scholar
• BEARDWELL CG, HINDLEY AC, WLIKINSON PM, TODD ID, RIBEIRO GG, BU’LOCK D: Trilostane in the treatment of advanced breast cancer. Cancer Chemother. Pharmacol. (1983) 10:158-160.
   PubMedGoogle Scholar
• THURLIMANN B, VARINI M, SENN HJ: Endocrine therapy with trilostane in pretreated advanced breast cancer. Tumor Diagnostik and Therapie (1990) 11:5-7.
   Google Scholar
• WILLIAMS CJ, BARLEY V, BLACKLEDGE G, HUTCHEON A, KAYE S, SMITH D, KEEN C, WEBSTER DJT: Multicenter study of trilostane: a new hormonal agent in advanced postmenopausal breast cancer. Cancer Treatment Reports (1987) 71:1197-1200.
   PubMedGoogle Scholar
• HARVEY HA, SANTEN RJ, DEMERS LM, LIPTON A, WHITE-HERSHEY D, SHAFIK A: The separate and combined hormonal and clinical effects of trilostane and hydrocortisone in metastatic breast cancer. Breast Cancer Res. Treat. (1986) 8:82.
   Google Scholar
• WILLIAMS CJ, BARLEY VL, BLACKLEDGE GR et al.: Multicentre cross-over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer. Clinical Oncology (1995) 7:87-92.
   Google Scholar
• ROSE C, MOURIDSEN HT, WILDIERS J, PARIDAENS R, SYLVESTER R, ROTMMENSZ N: Second line therapy in advanced breast cancer. A randomized phase II study, comparing aminoglutethimide plus hydrocortisone vs medroxyprogesterone acetate vs trilostane plus hydrocortisone vs hydrocortisone: an EORTC study. Eur. Organ. Res. Treat Cancer (1987) 18:89-97.
   Google Scholar
• HAYWARD GL, RUBENS RD, CARBONE PP, HEUSON JC, KUMAOKA S, SEGALOFF A: Assessment of response to therapy in advanced breast cancer. Br. J. Cancer (1977) 35:292-296.
   PubMed Web of Science ®Google Scholar
• LEONARD RCF, BUNDRED N, CANNEY P et al.: Meta analysis of Trilostane (Modrenal®) advanced post-menopausal breast cancer evaluated by prior exposure to anti-oestrogen treatments. Eur. J. Cancer (2003) 1(Suppl):47.
   Google Scholar
• KOMANICKY P, SPARK RF, MELBY JC: Treatment of Cushing’s syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. J. Clin. Endocrinol. Metab. (1978) 47:1042-1051.
   PubMed Web of Science ®Google Scholar
• DEWIS P, ANDERSON C, BUL’LOCK DE, EARNSHAW R, KELLY WF: Experience with trilostane in the treatment of Cushing’s syndrome. Clin. Endocr. (1983) 18:533-540.
   PubMed Web of Science ®Google Scholar
• SEMPLE CG, BEASTALL GH, GRAY CE, THOMSON JA: Trilostane in the management of Cushing’s syndrome. Acta Endocr. (1983) 102:107-110.
   PubMedGoogle Scholar
• BRADDOCK JA, CHURCH DB, ROBERTSON ID, WATSON AD: Trilostane treatment in dogs with pituitary dependent hyperadrenocorticism. Aust. Vet. J. (2003) 81:600-607.
   PubMedGoogle Scholar
• SIEBER-RUCKSTUHL N, BORETTI FS, WENGER M, MASER-GLUTH C, REUSCH CE: Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Domestic Animal Endocrinology (2006) 31:63-75.
   PubMedGoogle Scholar
• NEIGER R, RAMSAY I, O’CONNOR J, HURLEY KJ, MOONEY CT: Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism. Vet. Rec. (2002) 150:799-804.
   PubMed Web of Science ®Google Scholar
• NAKADA T, KAZAM T, KOIKE H, YOSHIKAWA M, ISHIKAWA S, KATAYAMA T: Primary aldosteronism treated by trilostane (3-β-hydroxysteroid dehydrogenase inhibitor). Urology (1985) 25:207-214
   PubMedGoogle Scholar
• NOMURA K, DEMURA H, HORIBA N, SHIZUME K: Long-term treatment of idiopathic hyperaldosteronism using trilostane. Acta Endocrinol. (1986) 113:104-110.
   PubMedGoogle Scholar
• MALOUITRE SD, BARKER S, PUDDEFOOT JR JALILI J, GLOVER HR, VINSON GP: Regulation of hepatic steroid receptors and enzymes by the 3β-hydroxysteroid dehydrogenase inhibitor trilostane. J. Steroid Biochem. Molecular Biol. (2006) in press.
   Google Scholar
• TORLAKOVIC E , LILLEBY W, BERNER A, TORLAKOVIC G, CHIBBAR R, FURRE T, FOSSÅ SD: Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma. Int. J. Cancer (2005) 117:381-386.
   PubMed Web of Science ®Google Scholar